myNEO evolves into myNEO Therapeutics

myNEO evolves into myNEO Therapeutics to reflect its new strategy to develop off-the-shelf cancer vaccine immunotherapeutics.

myNEO, a biotech company focused on exploiting “dark genome” targets to develop novel therapeutic cancer vaccines, today announces its new name – myNEO Therapeutics. The new name reflects the company's transition from an immunogenomic profiling expert towards an integrated drug discovery company focused on the development of a pipeline of therapeutic cancer vaccines.

Since the company was founded in 2018, it has developed and patented proprietary Artificial Intelligence (AI) algorithms that are state-of-the art in identifying novel cancer antigens, allowing optimal selection of the best cancer targets for use in immunotherapies.

Building on this deep knowledge, internal research efforts have revealed a novel class of lncRNA-derived “dark genome” antigens which myNEO Therapeutics has named “camyotopes”. These tumor-derived epitopes originate from the non-coding part of the genome, or dark genome, which is increasingly associated with a variety of diseases including cancer.

Following the discovery and validation of a number of camyotopes, myNEO Therapeutics has made rapid progress in advancing its first therapeutic product, CAMYO-01, towards the clinic. CAMYO-01 incorporates a pool of colorectal cancer-specific camyotopes formulated into an mRNA-based vaccine.

Unlike personalized vaccines that require patient-unique targets and upfront genomic analysis of each patient's tumor, camyotopes are conserved in more than 95% of the target cancer patient population. As such, treatments based on these targets can be made readily available off-the-shelf with no need for expensive and time-consuming tumor screening thereby improving access and providing a significant benefit to patients.